-
Dr. Myron Schwartz: The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer
Primary liver cancer is one of the common malignant tumors worldwide. With the development of modern biomedical technology, clinical surgical techniques, and minimally invasive treatment techniques, the surgical treatment level of liver cancer has made significant progress. At the recently concluded global academic event in the field of liver cancer – the 17th Annual Meeting…
-
Dr. Masatoshi Kudo: “T+A” Shows Significant Clinical Benefits in Intermediate-Stage HCC Patients Unsuitable for TACE Treatment
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor posing a significant threat to human health with considerable heterogeneity. Specifically, intermediate-stage HCC spans a range from liver function reserve ChHepatology Digest-Pugh A grade (5 points) to B grade (9 points), tumor sizes from 5 cm to >10 cm, and the number of nodules from 4 to…
-
ILCA 2023 | Exploration of Immunotherapy as Neoadjuvant Treatment in Reducing Postoperative Recurrence of HCC
Immune checkpoint inhibitors (ICIs) have been widely used in the clinical treatment of patients with advanced hepatocellular carcinoma (HCC), significantly improving their survival. While early-stage HCC can be cured with hepatectomy, up to 70% of patients may experience tumor recurrence within two years post-surgery. Therefore, the feasibility of perioperative ICI use to effectively inhibit tumor…
-
ILCA 2023 | Liver Frailty Index as an Independent Predictor of Mortality in Advanced HCC Patients Undergoing Systemic Treatment
Systemic treatment can extend the overall survival of patients with advanced hepatocellular carcinoma (HCC). However, results vary among individuals, and the predictive factors for survival rates in advanced HCC patients are still unclear. Previous studies have shown that the patient’s frailty index is related to adverse outcomes in liver cirrhosis and liver transplant recipients. It…
-
ILCA 2023 | VETC Evaluation Predicts Clinical Benefit of Anti-Angiogenic Treatment in Advanced HCC Patients
Hepatocellular carcinoma (HCC) is a highly malignant tumor, and one of its main characteristics is its rich vascular supply. Therefore, anti-angiogenic drugs have become one of the most important choices in the systematic treatment of HCC. In recent years, as research on HCC has deepened, researchers have discovered a unique vascular pattern in HCC tissue.…
-
Dr. Nathalie Ganne-Carrié: Exploration and Clinical Practice of Biomarkers for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide. Although the prognosis for HCC patients is generally poor, if diagnosed early, the 5-year survival rate can exceed 70%. Currently, the diagnosis of HCC without pathological evidence mainly relies on analyzing serum alpha-fetoprotein (AFP) levels and radiological diagnosis. Therefore, exploring early diagnostic biomarkers for…
-
Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1…
-
ILCA 2023 | Dynamic Changes in Circulating Tumor DNA Assist in Guiding and Evaluating Clinical Treatment of Liver Cancer
Circulating tumor DNA (ctDNA) refers to free tumor DNA fragments located in peripheral circulation. These free nucleic acids not only provide a comprehensive view of tumor genetics but also indirectly reflect tumor progression, heterogeneity, and invasive ability. They represent a promising non-invasive biomarker in cancer treatment. Dr. Claudia Campani from the University of Paris delivered…
Connecting Medical Expertise through Media